Based in New Jersey, 

Becton, Dickinson and Company (BDX - Analyst Report)

 is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. These products are used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

Currently, Becton, Dickinson has a Zacks Rank #3 (Hold) but that could change following its second-quarter fiscal 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below: 

Earnings: Becton, Dickinson’s adjusted earnings of $2.18 per share beat the Zacks Consensus Estimate by 17 cents and increased 44.7% year-over-year on a currency-neutral basis.
 
Revenues: Adjusted revenues amounted to $3.07 billion, up 55.2% from the year-ago quarter on a currency-neutral basis. Revenues beat the Zacks Consensus Estimate of $3.06 billion.

Key Stats: Becton medical generated revenues of $2.14 billion, up 99.5% on a year-over-year basis. BD Lifesciences generated revenues of $936 million, up 3.4% from the year-ago quarter.

Major Factors: On a comparable basis, adjusted U.S. revenues increased 5.7%. International revenues increased 4.8% on a currency-neutral basis in the reported quarter.
 
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.